Management of a patient with primary mucinous testicular adenocarcinoma as a rare case with adjuvant and metastatic sequential treatments. (September 2020)

• Record Type: Journal Article
• Authors: Tanriverdi, Ozgur; Tarimer, Mehmet Levent; Pak, Ceren Deniz; Uylas, Selcuk; Alkan, Ali; Dere, Yelda; Yazici, Ayse; Sen, Serdar; Sahin, Hayrettin
• Is Part Of: Journal of oncology pharmacy practice. Volume 26:Number 6(2020)
• Page Start: 1520
• Page End: 1523
• Publication Date: 2020-09
• Subjects: Testicular cancer -- mucinous adenocarcinoma -- mucinous tumors; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220903374
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Mucinous adenocarcinomas of the testicular surface epithelial tumors are very rare and are similar to malignant ovarian-type surface epithelial tumors. Although only 32 cases have been reported to date, there are only five cases of primary testicular mucinous carcinoma with access to literature in English. So there is still limited information about clinical, etiopathogenesis and treatment options. Case report: In this article, we discuss a 56-year-old male patient diagnosed with testicular mucinous adenocarcinoma due to its rarity in the light of literature review. Management and outcome: We preferred cisplatin-paclitaxel regimen for adjuvant treatment. We then used sequential treatments including oxaliplatin, 5-fluorourasil, etoposide, gemcitabine, and docetaxel to treat metastatic disease. The patient underwent lung metastasectomy for the first relapse. The patient was diagnosed in November 2013 and the response to treatment was evaluated in December 2019 and stable disease was detected. The patient, who has a total survival of 73 months, is still under treatment. Discussion: Excluding malign transformation and borderline mucinous testicular tumors from mucinous cystadenomas of the testis, the knowledge on carcinogenesis, clinical course, and treatment of primary testicular mucinous adenocarcinomas is very limited.